Malignant News and Research

RSS

Researchers clone T-cell receptor that binds to antigens associated with prostate and breast cancer

Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.

14 Sep 2012

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

13 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Link between recreational marijuana use and increased risk of testicular cancer

A new study from the University of Southern California (USC) has found a link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer that tend to carry a somewhat worse prognosis.

10 Sep 2012

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.

7 Sep 2012

Germline BAP1 mutations associated with novel cancer syndrome

University of Hawai'i Cancer Center researchers have discovered germline BAP1 mutations are associated with a novel cancer syndrome characterized by malignant mesothelioma, uveal melanoma, cutaneous melanoma and atypical melanocytic tumors. Germline mutations are hereditary gene defects that are present in every cell.

7 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease (GVHD).

6 Sep 2012

Fusion-negative prostate tumours display more aberrant DNA methylations

In about half of all prostate tumours, there are two genetic areas that are fused with one another. When this is not the case, the exact way cancer cells originate in prostate tumours was not clear until now.

5 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

The primitive stem cell state we created is called an “induced pluripotent stem cell” (iPSC). iPSC are a new, unique, and artificially-created type of stem cell that were first described in 2006 by a Japanese scientist named Shinya Yamanaka.

4 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

31 Aug 2012

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.

From Quest Diagnostics 31 Aug 2012

Endoscopic microsurgery effective for giant rectal adenomas

Transanal endoscopic microsurgery on large rectal adenomas provides results comparable to or better than those reported for alternative techniques, shows a UK study.

29 Aug 2012

Malignant News and Research

Researchers clone T-cell receptor that binds to antigens associated with prostate and breast cancer

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

'No malignancy risk' with biologic response modifiers

Link between recreational marijuana use and increased risk of testicular cancer

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Germline BAP1 mutations associated with novel cancer syndrome

Sorafenib could be effective against multiple myeloma

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

Fusion-negative prostate tumours display more aberrant DNA methylations

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

New drug combines photothermia and chemotherapy to help fight cancer

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Quest Diagnostics announces availability of TERC test for cervical cancer

Endoscopic microsurgery effective for giant rectal adenomas

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News